Palvella Therapeutics, Inc. (PVLA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Palvela Second Quarter 2025 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Bohan Wei, Vice President of Corporate Development. Please go ahead. Thank you, Operator. Good morning, and thank you for joining the Palvela Therapeutics Q2 2025 Financial Results and Corporate Update Call. As a reminder, our press release detailing today's announcements can be found in the Investors section of our website at www.palvelatx.com. On today's call, we are joined by Wes Koppenen, our Chief Executive Officer. Jeff Martini, our Chief Scientific Officer, and Matt Korenberg, our Chief Financial Officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. And now I'll turn the call over to Wes. Thank you, Bohan. Good morning, everyone. And thank you all for joining today's call. Paul Vela is now nine months into our journey as a publicly traded company. And I want to state at the outset of th...